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Abstract
When critically ill patients with pancreatitis develop infection of the
pancreas, the ongoing management of such patients becomes
difficult. Sufficient evidence supports the use of broad-spectrum
antibiotic prophylaxis to prevent the development of bacterial
infection. Since fungal infection is also a relatively common
complication of severe pancreatitis – particularly when broad-
spectrum antibiotics are used – it seems logical that fungal
prophylaxis may be an important component of management. In
this issue of Critical Care, two expert groups debate the merits of
antifungal prophylaxis in patients with acute necrotizing
pancreatitis who are receiving antibiotics.
The scenario
A 47 year old male presents to your intensive care unit with
evidence of severe pancreatitis. He develops multi-organ
failure, including the need for intubation/mechanical
ventilation, inotropes and dialysis. Although the cause of his
pancreatitis is not clear, there is evidence of pancreatic
necrosis on abdominal imaging. As a result you start broad-
spectrum antibiotics and plan on-going management with the
surgical team. Given that you understand these patients are
at high risk for fungal infection, you wonder about the role of
prophylactic antifungal agents.
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Pro: Antifungal prophylaxis should be parallel to any antimicrobial prophylaxis
Philippe Eggimann
Acute pancreatitis is severe in only 20% of patients with the
disease, but despite continuous advances in supportive
treatments, the prognosis for these patients has not improved
over the past decades. Necrosis of the pancreatic tissue
develops early in 25% to 40% of patients, and for those who
survive to an eventual initial multiple organ failure, mortality
rates up to 60% have been linked to the high proportion of
superinfections [1]. Gram-negative bacteria and fungi
progressively colonize the bowel within the first two weeks of
the disease and further translocate into necrotic tissues [2].
Bacterial and fungal infections have been documented in
patients not exposed to prior antimicrobials at rates of 40%
to 70% [3] and 5% to 8% [2,4,5], respectively. Infected
pancreatic necrosis or, for some experts, a high suspicion of
it requires aggressive surgical debridement, itself associated
with further increased morbidity and mortality [6,7].
This vicious circle has prompted the testing of early
antimicrobial prophylaxis in acute pancreatitis. The results of
at least 12 studies suggest that morbidity and mortality are
reduced when prophylaxis is restricted to the most severe
cases. Despite considering the same data compiled in
several meta-analyses and systematic reviews, experts and
scientific organizations have drawn different conclusions and
proposed contradictory guidelines [1,6,8]. Nevertheless,
antimicrobial prophylaxis has become a standard practice in
many institutions. In a UK survey performed in 1997, as many
as 90% of surgeons prescribed it, as did, more recently, 73%
of 329 members of the European chapter of the International
Hepato-Biliary Association [9].
Candida has been found in 15% to 70% of infected necrotic
tissues of patients requiring surgery, and these high
proportions have been repeatedly related to prior antibiotic
exposure, which promotes the overgrowth of unaffected micro-
organisms [2,4,7]. In addition, pancreatic fungal infections may
be associated with further increased morbidity and mortality
[2,4,5,8].
The good safety profile and the excellent bioavailability of
triazole compounds in pancreatic tissues make them good
candidates for antifungal prophylaxis, but only limited data are
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available for their use in severe acute pancreatitis [2,4,10]. In
addition, the prophylactic trials in surgical patients that have
been carried out have included only a few patients with
pancreatitis. Indirect evidence of potential protection comes
from trials testing selective digestive decontamination, in
which lower candidiasis and mortality rates have been
reported [5]. In a unique open randomised study, He and
colleagues [11] investigated the effect of prophylaxis in a
series of 73 severe acute pancreatitis cases. Compared to
controls, garlicin and fluconazole reduced the rates of fungal
infections from 30% to 16% (p < 0.05) and 9% (p < 0.01),
respectively.
These data are clearly insufficient to support evidence-based
recommendations about antifungal prophylaxis in acute
pancreatitis. However, according to the preceding argu-
ments, I would recommend adding antifungal prophylaxis
with a triazole compound in any patients receiving
antibacterial prophylaxis. This prophylaxis may not only
prevent infection of necrotic pancreatic tissue, but also delay
the need for surgery. As early surgery within the first 2 weeks
has been associated with higher mortality rates, this may
have an impact on the outcome of the patients [1,6].
Delayed surgery may allow a more conservative approach,
with the use of a minimally invasive procedure, such as extra-
abdominal lumbar retroperitoneal debridement on well
circumscribed collections, for which promising preliminary
results have been reported [6,7].
Con: Prevalence and risks of fungal colonisation of pancreatic necrosis
Saurabh Jamdar and Ajith K Siriwardena
Fungal colonisation of pancreatic tissue is a feared compli-
cation of severe acute pancreatitis. Invasive candidiasis can
be associated with mortality rates in excess of 40% [12] and,
once colonised, eradication of fungi from the poorly perfused
peri-pancreatic tissues of the retroperitoneum may be
difficult.
The risks of fungal colonisation of pancreatic necrosis are
brought into focus in contemporary critical care practice as a
result of recent trends in antibiotic use and trends in surgical
debridement of infected necrosis. Several small randomised
trials of antibiotic prophylaxis in severe acute pancreatitis
[13-15] together with a meta-analysis [16] and a Cochrane
systematic review [17] have indicated an improvement in
outcome in those patients receiving antibiotics. This evidence
has resulted in antibiotic prophylaxis being recommended in
several published guidelines for the treatment of severe acute
pancreatitis [8,18,19]. Although the Cochrane systematic
review [17] concluded that there was no increased
preponderance of fungal infection in patients in the treatment
arms compared to placebo, this finding is not necessarily at
odds with evidence of increased prevalence of fungal
colonization in critically ill surgical patients and, recently,
Isenmann and colleagues [5] demonstrated that prolonged
antibiotic therapy was associated with a high incidence of
Candida-infected pancreatic necrosis. The advent of
antibiotic prophylaxis in the management of severe acute
pancreatitis has probably also contributed to a significant
shift in the profile of pathogenic organisms. The resistant flora
encountered following such therapy include multi-resistant
Gram-positive cocci, Gram-negative bacilli and fungi.
To date, no randomised trial has examined the role of anti-
fungal prophylaxis in patients with severe acute pancreatitis
and practice guidelines must thus be based on extrapolation
of current evidence. The Ostrosky-Zeichner clinical prediction
rule [20] defines patients with pancreatitis (with central lines
and receiving broad spectrum antibiotics) as being at high
risk for fungal colonisation. Incorporation of evidence from
studies in parallel patient populations is central to the
construction of a rational policy for severe acute pancreatitis
and the recent detailed meta-analysis of fluconazole
prophylaxis in critically ill surgical patients concluded that,
although treatment was associated with lower fungal
colonisation rates, there was no evidence of a reduction in
mortality [21]. In data specific to acute pancreatitis, He and
colleagues [11] from Hunan, China, demonstrated in a study
of 70 patients that colonisation in individuals receiving
fluconazole prophylaxis (n = 22) was 9% compared to 23
control patients in whom colonisation rates were 30%. A
retrospective analysis of 46 patients with infected pancreatic
necrosis demonstrated that the early administration of
antifungal therapy (defined as at least 48 hours before
surgical intervention) reduced subsequent fungal infection
rates but not mortality [22].
Synthesising this evidence into a practical management
algorithm would suggest that there are limited grounds for
routine antifungal prophylaxis in patients with severe acute
pancreatitis even if these patients are receiving antibiotic
therapy. The subset of patients with on-going disease
requiring prolonged critical care support, where antibiotic
prophylaxis has transformed into specific broad-spectrum
antimicrobial therapy and, in particular, where trans-abdominal
percutaneous drains are in place (in addition to central venous
catheters), can be regarded as a subset of critically ill patients
with high on-going organ dysfunction scores where antifungal
prophylaxis can be considered. Even in this setting, it must be
acknowledged that there is little evidence that antifungal
prophylaxis is associated with a reduction in mortality and,
further, that this intervention may be associated with a higher
incidence of resistant candidal species [21].
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Pro’s response: Both antimicrobial and antifungal prophylaxis should be restricted to a limited
number of critically ill patients
Philippe Eggimann
I agree with the outstanding arguments of my opponent.
In addition, recent evidence further supports the generalisation
of antimicrobial prophylaxis [23]. While waiting for the results
of eventual large randomised studies, we need to propose a
simplified pragmatic approach for the daily care of critically ill
patients admitted for necrotizing pancreatitis.
Currently, according to the ecological impact of antimicrobial
prophylaxis, antifungals should be considered for all patients
receiving it. However, my second recommendation will be to
strongly restrict both antimicrobial and antifungal prophylaxis
to the subset of the most severely ill patients, carefully
selected after extensive diagnostic workup [24].
Con’s response: Antifungal prophylaxis does not reduce mortality in severe acute pancreatitis
Saurabh Jamdar and Ajith K Siriwardena
Dr Eggiman’s key point is that co-prescription of an antifungal
at the time of commencement of antibiotic prophylaxis may
”delay the need for surgery”. There is now broad consensus
that surgical intervention for pancreatic necrosis should be
deferred, if possible, during the first 21 days. However, there
is no suggestion that antifungal therapy helps to defer
intervention. In contrast, routine use of antifungal therapy is
not only over-used but is likely to encourage the emergence
of resistant species in precisely those patients who are
eventually most likely to require specific antifungal treatment:
patients with severe acute pancreatitis undergoing
radiological or surgical intervention.
Competing interests
PE has collaborated on several industry-sponsored clinical
trials since 1990. He has served on an advisory board and/or
sponsorized meetings and/or lectures for B-Braun, Cook
Critical Care, Lilly, Medex, Merck Sharp & Dohme-Chibret,
Pfizer, Roche and Wyeth-Lederle.
References
1. Whitcomb DC: Clinical practice. Acute pancreatitis. N Engl J
Med 2006, 354:2142-2150.
2. Shanmugam N, Isenmann R, Barkin JS, Beger HG: Pancreatic
fungal infection. Pancreas 2003, 27:133-138.
3. Beger HG, Rau B, Mayer J, Pralle U: Natural course of acute pan-
creatitis. World J Surg 1997, 21:130-135.
6. Beattie GC, Mason J, Swan D, Madhavan KK, Siriwardena AK:
Outcome of necrosectomy in acute pancreatitis: the case for
continued vigilance. Scand J Gastroenterol 2002, 37:1449-1453.
7. Besselink MG, de Bruijn MT, Rutten JP, Boermeester MA, Hofker
HS, Gooszen HG: Surgical intervention in patients with necro-
tizing pancreatitis. Br J Surg 2006, 93:593-599.
8. Nathens AB, Curtis JR, Beale RJ, Cook DJ, Moreno RP, Romand
JA, Skerrett SJ, Stapleton RD, Ware L, Waldmann CS: Manage-
ment of the critically ill patient with severe acute pancreatitis.
Crit Care Med 2004, 32:2524-2536.
9. King NK, Siriwardena AK: European survey of surgical strate-
gies for the management of severe acute pancreatitis. Am J
Gastroenterol 2004, 99:719-728.
4. De Waele JJ, Vogelaers D, Blot S, Colardyn F: Fungal infections
in patients with severe acute pancreatitis and the use of pro-
phylactic therapy. Clin Infect Dis 2003, 37:208-213.
5. Isenmann R, Schwarz M, Rau B, Trautmann M, Schober W,
Beger HG: Characteristics of infection with Candida species
in patients with necrotizing pancreatitis. World J Surg 2002,
26:372-376.
10. Shrikhande S, Friess H, Issenegger C, Martignoni ME, Yong H,
Gloor B, Yeates R, Kleeff J, Büchler M: Fluconazole penetration
into the pancreas. Antimicrob Agents Chemother 2000, 44:
2569-2571.
11. He YM, Lv XS, Ai ZL, Liu ZS, Qian Q, Sun Q, Chen JW, Lei DX,
Jiang CQ, Yuan YF: Prevention and therapy of fungal infection
in severe acute pancreatitis: A prospective clinical study.
World J Gastroenterol 2003, 9:2619-2621.
12. Eggimann P, Francioli P, Bille J, Schneider R, Wu MM, Chapuis
G, Chiolero R, Pannatier A, Schilling J, Geroulanos S, et al.: Flu-
canozole prophylaxis prevents intra-abdominal candidiasis in
high-risk surgical patients. Crit Care Med 1999, 27:1066-
1072.
13. Pederzoli P, Bassi C, Vesentini S, Camedelli A: A randomised
multicentre clinical trial of antibiotic prophylaxis of septic
complications in acute pancreatitis with impenem. Surg
Gynecol Obstet 1993, 176:480-483.
14. Sainio V, Kemppainen E, Puolakkainen P, Taavitsainen M, Kivisaari
L, Valtonen V, Haapiainen R, Schroder T, Kivilaakso E: Early
antibiotic treatment in acute necrotising pancreatitis. Lancet
1995, 346:663-667.
15. Delcenserie R, Yzet T, Ducroix JP: Prophylactic antibiotics in
treatment of severe acute pancreatitis. Pancreas 1996, 13:
198-201.
16. Sharma VK, Howden CW: Prophylactic antibiotic administra-
tion reduces sepsis and mortality in acute necrotizing pancre-
atitis: a meta-analysis. Pancreas 2001, 22:28-31.
17. Bassi C, Larvin M, Villatoro E: Antibiotic therapy for prophylaxis
against infection of pancreatic necrosis in acute pancreatitis.
Cochrane Database Syst Rev 2003, 4:CD002941.
18. Working party of the British Society of Gastroenterology; Associ-
ation of Surgeons of Great Britain and Ireland; Pancreatic Society
of Great Britain and Ireland; Association of Upper GI Surgeons of
Great Britain and Ireland: UK guidelines for the management
of acute pancreatitis. Gut 2005, 54(Suppl 3):iii1-9.
19. Uhl W, Warshaw A, Imrie C, Bassi C, McKay CJ, Lankisch PG,
Carter R, Di Magno E, Banks PA, Whitcomb DC, et al.; Interna-
tional Association of Pancreatology: IAP Guidelines for the sur-
gical management of acute pancreatitis. Pancreatology 2002,
2:565-573.
20. Paphitou NI, Ostrosky-Zeichner L, Rex JH: Rules for identifying
patients at increased risk for candidal infections in the surgi-
cal intensive care unit: approach to developing practical crite-
ria for systematic use in antifungal prophylaxis trials. Med
Mycol 2005, 43:235-243.
21. Shorr AF, Chung K, Jackson WL, Waterman PE, Kollef MH: Flu-
conazole prophylaxis in critically ill surgical patients: a meta-
analysis. Crit Care Med 2005, 33:1928-1935.
22. King NK, Siriwardana HP, Wood B, Siriwardena AK: Trends in
fungal colonization of pancreatic necrosis in patients under-
going necrosectomy for acute pancreatitis. HPB 2005, 7:120-
123.
23. Moyshenyat I, Mandell E, Tenner S: Antibiotic prophylaxis of
pancreatic infection in patients with necrotizing pancreatitis:
rationale, evidence, and recommendations. Curr Gastroenterol
Rep 2006, 8:121-126.
24. Eggimann P, Garbino J, Pittet D: Management of Candida
species infections in critically ill patient. Lancet Infect Dis
2003, 3:772-785.
Critical Care    Vol 10 No 5 Eggimann et al.
Page 4 of 4
(page number not for citation purposes)
